These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37322804)

  • 1. Remnant cholesterol in the era of intensive lipid-lowering therapies.
    Wadström BN; Wulff AB; Pedersen KM; Nordestgaard BG
    Eur Heart J; 2023 Sep; 44(36):3483. PubMed ID: 37322804
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Wulff AB; Nordestgaard BG; Tybjærg-Hansen A
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):660-668. PubMed ID: 29348120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Khan SU; Rahman H; Okunrintemi V; Riaz H; Khan MS; Sattur S; Kaluski E; Lincoff AM; Martin SS; Blaha MJ
    J Am Heart Assoc; 2019 Apr; 8(7):e011581. PubMed ID: 30898075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant Cholesterol.
    Masson W; Lobo M; Molinero G; Siniawski D
    Arq Bras Cardiol; 2017 Jun; 108(6):526-532. PubMed ID: 28699976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term intensive cholesterol control on the plaque progression in elderly based on CTA cohort study.
    Sun T; Wang Y; Wang X; Hu W; Li A; Li S; Xu X; Cao R; Fan L; Cao F
    Eur Radiol; 2022 Jul; 32(7):4374-4383. PubMed ID: 35226154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.
    Langlois MR; Nordestgaard BG; Langsted A; Chapman MJ; Aakre KM; Baum H; Borén J; Bruckert E; Catapano A; Cobbaert C; Collinson P; Descamps OS; Duff CJ; von Eckardstein A; Hammerer-Lercher A; Kamstrup PR; Kolovou G; Kronenberg F; Mora S; Pulkki K; Remaley AT; Rifai N; Ros E; Stankovic S; Stavljenic-Rukavina A; Sypniewska G; Watts GF; Wiklund O; Laitinen P;
    Clin Chem Lab Med; 2020 Mar; 58(4):496-517. PubMed ID: 31855562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
    Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
    J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment.
    Varbo A; Benn M; Nordestgaard BG
    Pharmacol Ther; 2014 Mar; 141(3):358-67. PubMed ID: 24287311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on low-density lipoprotein cholesterol goal achievement.
    Catapano AL
    Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials.
    Patti G; Spinoni EG; Grisafi L; Mehran R; Mennuni M
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):138-147. PubMed ID: 36102667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
    Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.
    Hsu HY; Lin CJ; Lee YS; Wu TH; Chien KL
    BMC Cardiovasc Disord; 2020 Jul; 20(1):334. PubMed ID: 32660417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new reality: achieving cholesterol-lowering goals in clinical practice.
    Gaw A
    Atheroscler Suppl; 2002 Apr; 2(4):5-8; discussion 8-11. PubMed ID: 11976071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
    Gencer B; Marston NA; Im K; Cannon CP; Sever P; Keech A; Braunwald E; Giugliano RP; Sabatine MS
    Lancet; 2020 Nov; 396(10263):1637-1643. PubMed ID: 33186535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease.
    Packard CJ
    Curr Atheroscler Rep; 2022 Mar; 24(3):133-142. PubMed ID: 35175548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age- and sex-specific reference values for non-HDL cholesterol and remnant cholesterol derived from the Nordic Reference Interval Project (NORIP).
    Ridefelt P; Hagström E; Svensson MK; Åkerfeldt T; Larsson A
    Scand J Clin Lab Invest; 2019; 79(1-2):39-42. PubMed ID: 30638091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.